Warrants

Silver One Resources (SLVRF) increased its private placement to $6,016,600 due to oversubscription, offering 21,487,857 units at $0.28 each, comprising one common share and a half-warrant. Warrants allow purchase of a share at $0.40 within three years. Proceeds will fund exploration/drilling and working capital. The offering is subject to TSX Venture Exchange approval and a four-month resale restriction. Silver One focuses on silver project development, including the Candelaria Mine in Nevada.

Defence Therapeutics (DTCFF) announced a non-brokered private placement to raise up to $1.2 million by offering debenture units priced at $1,000 each. Each unit includes an 8% convertible debenture (convertible at $0.60 per share) maturing in two years and 1,666 common share purchase warrants (exercisable at $0.75 per share for two years). Interest will be paid annually in cash or shares at the company’s discretion. Securities are subject to a four-month hold. The offering aims to fund the company’s antibody-drug conjugate (ADC) programs.

Revive Therapeutics (RVVTF) closed the first tranche of its private placement, raising $60,900 by issuing 2.9 million units at $0.021 each. It also settled $67,400 in debt by issuing 3.2 million units at the same price. Each unit includes a share and a warrant exercisable at $0.05 for 36 months. The proceeds will fund working capital and payables. Securities are subject to a hold period expiring December 9, 2025. The offering included 100,000 compensation options to an investment dealer.

Mainz Biomed (MYNZ) has priced a $3.0 million follow-on offering at $1.35 per unit, consisting of 2,222,222 units. Each unit includes one ordinary share (or pre-funded warrant) and one Series A warrant exercisable at $1.35, expiring in five years. Maxim Group LLC is the sole placement agent. The offering is expected to close around August 5, 2025, subject to customary conditions. The offering provides minimal capital and potential shareholder dilution.

DEFSEC Technologies Inc. (DFSC) announced the pricing of a CAD$6.8 million public offering consisting of units with common shares (or pre-funded warrants) and warrants. Each unit, priced at CAD$8.955, includes one share/warrant, with warrants exercisable at CAD$10.52 within five years. H.C. Wainwright & Co. is the placement agent. Closing is expected around July 25, 2025. Net proceeds will be used for working capital and general corporate purposes. The offering, while injecting capital, introduces potential dilution for existing shareholders.

Tharimmune (THAR) announced a $1.74 million registered direct offering consisting of common stock and warrants. Units are priced at $1.786, including one share or pre-funded warrant and a common warrant. President Street Global is the placement agent. Proceeds will fund working capital and general corporate purposes. The offering is expected to close around July 25, 2025. This funding aims to support Tharimmune’s work in immunology and inflammation therapies, including their clinical asset, TH104.

Netcapital (NCPL) announced a registered direct offering of 641,712 shares at $4.675 per share, aiming for $3 million in gross proceeds. A concurrent private placement offers unregistered short-term warrants for up to 641,712 shares at $4.55 each, potentially adding $2.9 million if fully exercised. Slated to close around July 17, 2025, with H.C. Wainwright & Co. as placement agent, the proceeds will repay promissory notes and fund working capital. The offering involves shareholder dilution with potential for further dilution.

Milestone Pharmaceuticals announced an underwritten public offering of common shares with Series A and Series B warrants, plus pre-funded warrants for certain investors. Proceeds will primarily fund the clinical development and U.S. commercial launch of its PSVT treatment candidate, etripamil, while covering working capital. TD Cowen, Piper Sandler, and Wells Fargo Securities are joint bookrunners, with H.C. Wainwright as lead manager. This financing supports Milestone’s transition toward commercialization, though it may dilute existing shareholders.

Aris Mining (TSX: ARIS; NYSE-A: ARMN) reminds holders that its TSX warrants (ARIS.WT.A) expire July 29, 2025. These “in-the-money” warrants (C$5.50 exercise vs. C$9.46 share price) offer immediate value. Approximately 48.2% (28M warrants) have been exercised, generating C$77M. Exercising the remaining 30.2M warrants by the deadline could provide the company an additional C$83M. CEO Neil Woodyer stated this expiry completes capital structure simplification efforts. Warrant holders must act promptly and confirm their broker’s deadlines.

Quince Therapeutics announced a securities purchase agreement to raise approximately $11.5 million upfront, with the potential for an additional $10.4 million if warrants are exercised. The financing, priced at a premium, will fund working capital, R&D, and general corporate purposes, extending its operational runway into Q2 2026 (or potentially H2 2026). The placement is led by Nantahala Capital and is set to close in June 2025.